Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

Puente, Javier; Laínez, Núria; Dueñas, Marta; Mendez-Vidal, María José; Esteban, Emilio; Castellano, Daniel; Martínez‐Fernández, Mónica; Basterretxea, Laura; Juan-Fita, María José; Antón, L. M.; León, Luís; Lambea, J.; Pérez-Valderrama, Begoña; Vázquez‐Estévez, Sergio; Suárez, Cristina; Muro, Xavier García del; Gallardo, Enrique; Maroto, José Pablo; Samaniego, Millie; Suarez-Paniagua, Beatriz; Sanz, Julián; Paramio, Jesús M.; Sogug,

doi:10.18632/oncotarget.16494

Cited by 21 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 In primary refractory patients with clear-cell metastatic renal cell carcinoma (MRCC), miR-628 was involved in significantly mediating prolonged survival. 24 In contrast, Prior et al (2014) suggested that upregulation of miR-628 is significantly correlated with decreased overall survival and time to progression in patients with MRCC. 25 In our study, we showed that miR-628 was downregulated in bone metastatic breast cancer cells.…”

Section: Discussionmentioning

confidence: 97%

MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1

Lin¹,

Gao²,

Yan³

et al. 2018

OTT

View full text Add to dashboard Cite

PurposeThe purpose of this study is to evaluate the effects of miR-628 on migration and invasion of breast cancer stem cells (CSCs), which are essential for tumor recurrence and metastasis.Materials and methodsQuantitative reverse transcription-polymerase chain reaction was used to determine the expression of microRNAs and mRNAs. A subpopulation of CD44+/CD24− breast CSCs were sorted by flow cytometry. Transwell assays were used to evaluate cell migration and invasion. Luciferase reporter assays were performed to verify whether miR-628 targeted SOS Ras/Rac guanine nucleotide exchange factor 1 (SOS1). pcDNA3.1(+)-SOS1 was constructed for overexpressing SOS1 after transfection.ResultsCompared with primary breast cancer cells, bone metastatic breast cancer cells showed significant downregulation of miR-628. The CD44+/CD24− breast CSC subpopulations in MDA-MB-231 and MCF-7 cell lines were analyzed and sorted. Transfection with an miR-628 mimic significantly suppressed the migration and invasion of these breast CSCs by targeting SOS1, which plays an essential role in epithelial-to-mesenchymal transition. Overexpression of SOS1 rescued miR-628-mediated migration and invasion by upregulating Snail and vimentin, and downregulating E-cadherin.ConclusionmiR-628 suppressed migration and invasion of breast CSCs of MDA-MB-231 and MCF-7 cells by directly targeting SOS1. Enhancement of miR-628 expression might be an effective strategy for managing breast cancer metastasis.

show abstract

Section: Discussionmentioning

confidence: 97%

MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1

Lin¹,

Gao²,

Yan³

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…The latest findings reveled that miR-628-5p served as a potential biomarker for the prognosis of patients with ovarian cancer 65 . The increased miR-628-5p was also associated with prolonged MRCC patients' survival 66 . The altered miR-628 expression may further mediate the progression of ductal carcinoma in situ to invasive breast cancer and lympho-vascular invasion 67 .…”

Section: Discussionmentioning

confidence: 89%

“…The abovementioned studies indicated that increased miR-628 expression may predict a better OS 25 , 26 , 66 . However, Gao's study 27 showed that there was no association of miR-628-3p expression with OS of GCA.…”

Section: Discussionmentioning

confidence: 95%

Diagnostic and prognostic value of microRNA-628 for cancers

Li¹,

Sun²,

Fu³

et al. 2018

J. Cancer

View full text Add to dashboard Cite

Background: Many studies manifested miRNA-628 (miR-628) was deregulated in various cancers, indicating that miR-628 might serve as a novel biomarker of cancer diagnosis and prognosis, but it's role was still uncertain. This study aimed to evaluate the value of miR-628 in various cancers for diagnosis and prognosis, as well as its predictive power in combination biomarkers.Materials and Methods: A literature search was performed using Medline (via PubMed), Embase, Web of Science databases, and Ovid platform up to November 2017. Meta-analysis was performed to provide summative outcomes. Quality assessment of each included study was performed.Results: Twelve articles with 20 studies were included in our meta-analysis, including 8 articles with 15 studies for diagnostic meta-analysis and 4 articles with 5 studies for prognostic meta-analysis. For the diagnostic meta-analysis of miR-628 alone, the overall pooled results for sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristic (SROC) curve (AUC) were 0.81 (95% CI: 0.62-0.91), 0.72 (95% CI: 0.48-0.88), 2.90 (95% CI: 1.50-5.40), 0.27 (95% CI: 0.14-0.50), 11.0 (95% CI: 4.00-25.00), and 0.84 (95% CI: 0.80-0.87), respectively. For the diagnostic meta-analysis of miR-628-related combination biomarkers, the above six parameters were 0.89 (95% CI: 0.84-0.92), 0.93 (95% CI: 0.82-0.97), 12.30 (95% CI: 4.70-32.50), 0.12 (95% CI: 0.08-0.19), and 100.00 (95% CI: 28.00-354.00), 0.93 (95% CI: 0.90-0.95), respectively. For the prognostic meta-analysis, patients with lower miR-628 had significant shorter overall survival than high expression of miR-628 (HR = 1.553, 95% CI: 1.041-2.318, z = 2.16, P = 0.031).Conclusions: This study confirms that miR-628 may be a promising biomarker for cancer diagnosis and prognosis. Expertly, microRNAs combination biomarkers could be a new alternative for clinical application.

show abstract

“…Variable Not identified Jasinski-Berger et al 21 Puente et al 33 and Prior et al 36 Overall, these studies suggest that miRNA 628-5p expression could be useful as a cancer biomarker associated with favorable or unfavorable outcome dependent upon cancer type, disease stage, and treatment. These studies are summarized in Table 1.…”

Section: Renal Cell Carcinomamentioning

confidence: 97%

“…Tissues from normal mucosa and tumor were collected from surgical specimens, and miRNA 628-5p was found to be uniformly downregulated in the cancer samples. 32 In another study, Puente et al 33 analyzed the expression of various genes and miRNAs relevant in pathways involved in RCC development such as the Notch, Hedgehog, Wnt, hypoxia, epithelial mesenchymal transition, and stem cell maintenance signaling in two groups of patients: long-term sunitinib responders and patients exhibiting resistance to the drug. miRNA 628-5p was found to be upregulated in long-term responders compared to the patients with primary therapy resistance.…”

Section: Introductionmentioning

confidence: 99%

Emerging role of microRNA 628-5p as a novel biomarker for cancer and other diseases

2019

View full text Add to dashboard Cite

MicroRNAs are a family of small, single-stranded RNAs that have key roles in regulating multiple signaling pathways within a cell. Studies have implicated aberrant expression of microRNAs in the development and progression of several pathologies including cancer. MicroRNAs are relatively stable and readily available in body fluids and tissues, making them desirable biomarkers for prognostic and diagnostic purposes in an array of diseases. MicroRNA 628 (5p/3p variants) is located in the 15q21.3 cancer-related region, and evidence suggests its association with various pathologies. The -5p mature variant, microRNA 628-5p, has been reported to be differentially expressed in various cancers, and its expression has been mostly associated with tumor suppression but there are few reports identifying its role in cancer progression. Several studies have also suggested its utility in diagnosis and prognosis of various cancers. Dysregulation of microRNA 628-5p has also been implicated in embryonal implantation defects, autism, immune modulation, myogenesis, cardiovascular disease, viral infection, and skeletal muscle repair. Here, we have provided a comprehensive review on available literature explaining the role of microRNA 628-5p as a potential cancer biomarker as well as briefly describe its function in other diseases and normal physiological conditions. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

show abstract

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

Cited by 21 publications

References 34 publications

MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1

MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1

Diagnostic and prognostic value of microRNA-628 for cancers

Emerging role of microRNA 628-5p as a novel biomarker for cancer and other diseases

Contact Info

Product

Resources

About